Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells

ISSN: 1566-5232 (Print)
ISSN: 1875-5631 (Online)


Volume 14, 6 Issues, 2014


Download PDF Flyer




Current Gene Therapy

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 29th of 164 in Genetics & Heredity

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 4.906
5 - Year: 4.087

Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells

Author(s): John Maher

Affiliation: CAR Mechanics Group, King's College London, King's Health Partners Integrated Cancer Centre, Department of Research Oncology, Guy's Hospital Campus, Great Maze Pond, London SE1 9RT, UK.

Abstract

The CD19 molecule is ubiquitously expressed throughout all stages of B-cell differentiation, but is not found on haemopoietic stem cells. Since most B-cell leukaemias and lymphomas retain CD19 expression, it represents an excellent target for immunotherapy of these malignant disorders. Over the past 10 years, compelling pre-clinical evidence has accrued to indicate that expression of a CD19-targeted chimeric antigen receptor (CAR) in peripheral blood T-cells exerts therapeutic efficacy in diverse models of B-cell malignancy. Building on this, clinical studies are ongoing in several centres in which autologous CD19-specific CAR T-cells are undergoing evaluation in patients with acute and chronic B-cell leukaemia and refractory lymphoma. Early data have generated considerable excitement, providing grounds to speculate that CAR-based immunotherapy will radically alter existing management paradigms in B-cell malignancy. The focus of this mini-review is to evaluate these emerging clinical data and to speculate on clinical prospects for this new therapeutic modality.

Keywords: Adoptive immunotherapy, CD19, chimeric antigen receptor, gene therapy, leukaemia, lymphoma.

Download Free Rights and Permissions

  
  



Article Details

Volume: 14
Issue Number: 1
First Page: 35
Last Page: 43
Page Count: 9
DOI: 10.2174/1566523213666131223130554
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science